Prednisone, cyclophosphamide, etoposide, and methotrexate regimens are derived from a metronidazole, etoposide, procarbazine and cyclophosphamide (PEPC) regimen regimen that differs from the traditional maximal Tolerance chemotherapy, and the use of low-dose chemotherapy, frequent drug therapy, the purpose is to anti-angiogenesis and reduce drug resistance. At present, the program in our treatment of relapsed or refractory PTCL patients effective, safe and controllable, but also look forward to other joint treatment, so as to achieve better curative effect. To provide new treatment options for such patients.
To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide, etoposide and methotrexate in relapsed or refractory PTCL.